Teva Pharmaceutical Industries Limited

Tel Aviv Stock Exchange:TEVA.TA

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Israel

Market Cap

USD 20.08 B

Share Price

USD 17.10

Avg Daily Volume

1,949,777

Change (1 day)

-0.70%

Change (1 year)

0.44%

Change (YTD)

-23.38%

Teva Pharmaceutical Industries Limited Common Stock Issued for the year ending December 31, 2024: USD 0.00

Teva Pharmaceutical Industries Limited Common Stock Issued is USD 0.00 for the year ending December 31, 2024. Common stock issued is cash received from issuing new shares of the company’s common stock.

Teva Pharmaceutical Industries Limited Common Stock Issued for the year ending December 31, 2023 was USD 0.00.
Teva Pharmaceutical Industries Limited Common Stock Issued for the year ending December 31, 2022 was USD 0.00.
Teva Pharmaceutical Industries Limited Common Stock Issued for the year ending December 31, 2021 was USD 0.00.
Teva Pharmaceutical Industries Limited Common Stock Issued for the year ending December 31, 2020 was USD 0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Common Stock Issued	Common Stock Repurchased	Free Cash Flow	Operating Cash Flow

Tel Aviv Stock Exchange: TEVA.TA

Teva Pharmaceutical Industries Limited

CEO	Mr. Richard D. Francis
IPO Date	Aug. 12, 2002
Location	Israel
Headquarters	124 Dvora Hanevi’a Street
Employees	37,000
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.